Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism
Background. Patients with chronic hepatitis B virus (HBV) are often treated with nucleoside/nucleotide antiviral agents and metabolic bone toxicity is a possible concern.Objective. To determine the relationships between fibroblast growth factor 23 (FGF23), a phosphaturic hormone, bone mineral densit...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-03-01
|
Series: | Annals of Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119303837 |
id |
doaj-bb7188e7b0ef46db8d80447d6b84672a |
---|---|
record_format |
Article |
spelling |
doaj-bb7188e7b0ef46db8d80447d6b84672a2021-06-09T05:51:10ZengElsevierAnnals of Hepatology1665-26812017-03-01162207214Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone MetabolismRamesh Saeedi0Ali Mojebi-Mogharar1Supna K. Sandhu2Joshua A. Dubland3Jo-Ann Ford4Masoud Yousefi5Morris Pudek6Daniel T. Holmes7Siegfried R. Erb8Wing C. Peter Kwan9David L Kendler10Eric M. Yoshida11Department of Pathology & Laboratory MedicineDepartment of Medicine, Division of GastroenterologyDepartment of Medicine, Division of EndocrinologyDepartment of Medicine, University of British Columbia, Vancouver, BC, CanadaDepartment of Medicine, Division of GastroenterologyDepartment of Medicine, University of British Columbia, Vancouver, BC, CanadaDepartment of Pathology & Laboratory MedicineDepartment of Pathology & Laboratory MedicineDepartment of Medicine, Division of GastroenterologyDepartment of Medicine, Division of GastroenterologyDepartment of Medicine, Division of EndocrinologyDepartment of Medicine, Division of Gastroenterology; Correspondence and reprint request:Background. Patients with chronic hepatitis B virus (HBV) are often treated with nucleoside/nucleotide antiviral agents and metabolic bone toxicity is a possible concern.Objective. To determine the relationships between fibroblast growth factor 23 (FGF23), a phosphaturic hormone, bone mineral density (BMD), and bone biochemical abnormalities in these patients.Material and methods. This is a cross-sectional observational study comparing HBV-infected subjects treated for at least one year with tenofovir (TDF), lamuvidine (LVD), entacavir (ETV), or not treated (CON). Patients with abnormalities in either calcium (Ca), phosphate (PO4), intact parathyroid hormone (iPTH) or FGF23 were further evaluated with BMD by DXA.Results. No difference in liver enzymes or renal function seen among groups, but hypophosphatemia was seen in all groups with the highest incidence with TDF-treat-ment (14%). FGF 23 levels were found to be elevated in 11.1% of TDF patients, 2.77% amongst controls. No elevations were found in the LVD or ETV groups. Among a subset of subjects (FGF23, PO4, and/or Ca abnormalities) who underwent further evaluation, 67% had insufficient 25-OH vitamin D, and 30% had elevated 24 h urinary Ca or PO4 excretion. No patients with FGF23 abnormalities had urine abnormalities. 40% had low DXA Z-score (<-2) at spine or hip but there was no difference between control and antiviral treatment groups and the mean FRAX score was 2.33% for major osteoporotic fractures and 0.29% for hip fracture.Conclusion. Abnormalities in bone metabolism, particularly involving vitamin D insufficiency, in HBV-treated subjects were observed with a small increased likelihood in TDF treated patients.http://www.sciencedirect.com/science/article/pii/S1665268119303837HBVFibroblast growth factor 23HypophosphataemiaBMDVitamin D |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ramesh Saeedi Ali Mojebi-Mogharar Supna K. Sandhu Joshua A. Dubland Jo-Ann Ford Masoud Yousefi Morris Pudek Daniel T. Holmes Siegfried R. Erb Wing C. Peter Kwan David L Kendler Eric M. Yoshida |
spellingShingle |
Ramesh Saeedi Ali Mojebi-Mogharar Supna K. Sandhu Joshua A. Dubland Jo-Ann Ford Masoud Yousefi Morris Pudek Daniel T. Holmes Siegfried R. Erb Wing C. Peter Kwan David L Kendler Eric M. Yoshida Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism Annals of Hepatology HBV Fibroblast growth factor 23 Hypophosphataemia BMD Vitamin D |
author_facet |
Ramesh Saeedi Ali Mojebi-Mogharar Supna K. Sandhu Joshua A. Dubland Jo-Ann Ford Masoud Yousefi Morris Pudek Daniel T. Holmes Siegfried R. Erb Wing C. Peter Kwan David L Kendler Eric M. Yoshida |
author_sort |
Ramesh Saeedi |
title |
Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism |
title_short |
Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism |
title_full |
Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism |
title_fullStr |
Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism |
title_full_unstemmed |
Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism |
title_sort |
lamivudine, entecavir, or tenofovir treatment of hepatitis b infection: effects on calcium, phosphate, fgf23 and indicators of bone metabolism |
publisher |
Elsevier |
series |
Annals of Hepatology |
issn |
1665-2681 |
publishDate |
2017-03-01 |
description |
Background. Patients with chronic hepatitis B virus (HBV) are often treated with nucleoside/nucleotide antiviral agents and metabolic bone toxicity is a possible concern.Objective. To determine the relationships between fibroblast growth factor 23 (FGF23), a phosphaturic hormone, bone mineral density (BMD), and bone biochemical abnormalities in these patients.Material and methods. This is a cross-sectional observational study comparing HBV-infected subjects treated for at least one year with tenofovir (TDF), lamuvidine (LVD), entacavir (ETV), or not treated (CON). Patients with abnormalities in either calcium (Ca), phosphate (PO4), intact parathyroid hormone (iPTH) or FGF23 were further evaluated with BMD by DXA.Results. No difference in liver enzymes or renal function seen among groups, but hypophosphatemia was seen in all groups with the highest incidence with TDF-treat-ment (14%). FGF 23 levels were found to be elevated in 11.1% of TDF patients, 2.77% amongst controls. No elevations were found in the LVD or ETV groups. Among a subset of subjects (FGF23, PO4, and/or Ca abnormalities) who underwent further evaluation, 67% had insufficient 25-OH vitamin D, and 30% had elevated 24 h urinary Ca or PO4 excretion. No patients with FGF23 abnormalities had urine abnormalities. 40% had low DXA Z-score (<-2) at spine or hip but there was no difference between control and antiviral treatment groups and the mean FRAX score was 2.33% for major osteoporotic fractures and 0.29% for hip fracture.Conclusion. Abnormalities in bone metabolism, particularly involving vitamin D insufficiency, in HBV-treated subjects were observed with a small increased likelihood in TDF treated patients. |
topic |
HBV Fibroblast growth factor 23 Hypophosphataemia BMD Vitamin D |
url |
http://www.sciencedirect.com/science/article/pii/S1665268119303837 |
work_keys_str_mv |
AT rameshsaeedi lamivudineentecavirortenofovirtreatmentofhepatitisbinfectioneffectsoncalciumphosphatefgf23andindicatorsofbonemetabolism AT alimojebimogharar lamivudineentecavirortenofovirtreatmentofhepatitisbinfectioneffectsoncalciumphosphatefgf23andindicatorsofbonemetabolism AT supnaksandhu lamivudineentecavirortenofovirtreatmentofhepatitisbinfectioneffectsoncalciumphosphatefgf23andindicatorsofbonemetabolism AT joshuaadubland lamivudineentecavirortenofovirtreatmentofhepatitisbinfectioneffectsoncalciumphosphatefgf23andindicatorsofbonemetabolism AT joannford lamivudineentecavirortenofovirtreatmentofhepatitisbinfectioneffectsoncalciumphosphatefgf23andindicatorsofbonemetabolism AT masoudyousefi lamivudineentecavirortenofovirtreatmentofhepatitisbinfectioneffectsoncalciumphosphatefgf23andindicatorsofbonemetabolism AT morrispudek lamivudineentecavirortenofovirtreatmentofhepatitisbinfectioneffectsoncalciumphosphatefgf23andindicatorsofbonemetabolism AT danieltholmes lamivudineentecavirortenofovirtreatmentofhepatitisbinfectioneffectsoncalciumphosphatefgf23andindicatorsofbonemetabolism AT siegfriedrerb lamivudineentecavirortenofovirtreatmentofhepatitisbinfectioneffectsoncalciumphosphatefgf23andindicatorsofbonemetabolism AT wingcpeterkwan lamivudineentecavirortenofovirtreatmentofhepatitisbinfectioneffectsoncalciumphosphatefgf23andindicatorsofbonemetabolism AT davidlkendler lamivudineentecavirortenofovirtreatmentofhepatitisbinfectioneffectsoncalciumphosphatefgf23andindicatorsofbonemetabolism AT ericmyoshida lamivudineentecavirortenofovirtreatmentofhepatitisbinfectioneffectsoncalciumphosphatefgf23andindicatorsofbonemetabolism |
_version_ |
1721389086743199744 |